Legal risks: the struggle for inheritance may affect the production of 130 medicines
A hereditary dispute over a major drug manufacturer, Kanonfarma, may lead to criminal proceedings. Diana Kokeladze, the widow of the company's founder, announced her intention to achieve this to Izvestia. She believes that her stepson illegally gained control of the business, although according to the will, most of the shares are assigned to her and her daughter. Kanonfarma has denied these claims and claims that the legality of the current distribution of shares has been confirmed by the courts. The company produces more than 130 medicines, including those included in the list of essential medicines. Russian business knows examples where hereditary disputes have nearly destroyed successful brands, such as Natura Siberica. Whether this threatens Kanonfarma and whether it may affect the provision of medicines is in the Izvestia article.
What are the heirs suing for?
Diana Kokeladze, the widow of the founder of the large pharmaceutical company Kanonfarma, told Izvestia that her stepson Vyacheslav Kokeladze had illegally established control over the company and was allegedly withdrawing large sums from it. She claims that she intends to seek the initiation of a criminal case on these facts. This will mean a new round of confrontation around the company, which has been going on for more than five years.
The founder of Kanonfarma, Merab Kokeladze, died in 2021. He left his heirs a business with an annual turnover of about 12 billion rubles. The company produces drugs for the treatment of diseases in the fields of cardiology, gastroenterology, neurology, and endocrinology. A number of them are included in the list of vital and essential medicines (VED) and the lists of preferential provision for the population.
Immediately after the entrepreneur's death, his relatives began arguing about the inheritance. On the one hand, his last wife Diana and daughter Camilla. On the other hand, the businessman's first wife, Elena, and her son, Vyacheslav.
Diana Kokeladze insists that, according to the will of the deceased, she and the businessman's daughter Camilla are entitled to 51% of the shares of Kanonfarma.
"The main asset is a pharmaceutical company," she said. — According to the will, it turned out that we own a controlling stake. Vyacheslav gets 46%, and his mother Elena gets 2%," she says.
However, in fact, this will was ignored, according to the interlocutor of Izvestia.
— Immediately after the funeral, Vyacheslav opened an inheritance case with his notary, without defining the circle of heirs. As a legitimate wife, I am entitled to a share, but the notary refused me. The company is being taken away from Meraba's daughter Camilla and me. 14 trials have already passed.
The woman noted that the inheritance case was opened in Moscow, but Vyacheslav Kokeladze "corresponded in Ingushetia." Prior to that, the heir, according to her, had not even been in the republic.
In addition, in April 2021, Vyacheslav's mother, Elena Kokeladze, appealed to the Nazran District Court of Ingushetia with a demand to recognize 350 shares of Kanonfarma as property acquired jointly in marriage and determine her share in the amount of 175 shares.
"In support of the claims, it is stated that from December 13, 1982 to January 16, 2008, the plaintiff was married to Merab Kokeladze. 350 shares of Kanonfarma Production CJSC were acquired in the marriage, which were owned by Merab Kokeladze at the time of the divorce," the document says (Izvestia has it). After the dissolution of the marriage, the shares were not alienated and their division was not carried out, it follows from the court ruling.
Initially, the court granted the claim in full. Then there were several revisions. But in the end, in 2025, the Nazran District Court again recognized the right to own disputed shares for Elena Kokeladze, and the Supreme Court of Ingushetia upheld the decision in March 2026.
Diana Kokeladze already disagreed with this, as well as the businessman's mother Zoya Thilava, who was not mentioned in the will.
— On July 21, 2026, the cassation was held in Ingushetia, but our arguments did not change the decision, — says the widow of the businessman. — The entire dispute over the shares is taking place in the Caucasus, and for all other property, apartments, cars, accounts — in Moscow.
In 2026, Kanonfarma Production entered the top of the best pharmaceutical companies in Russia according to Forbes. In terms of revenue, it is one of the 26 largest industry organizations in the country, and its figures significantly exceed the average revenue in the market, according to data on the Rusprofile website. So, in 2021, the company's revenue amounted to almost 12 billion rubles.
What was told in the company
In response to a request from the editorial board, Kanonfarma stated that the information provided by Diana Kokeladze was not true.
"According to the decision of the Nazran District Court of Ingushetia, which entered into force, in September 2025, Elena Kokeladze was recognized as the owner of 175 shares of Kanonfarma Production CJSC," the company said.
Representatives of Kanonfarma stressed that Diana Kokeladze, like other heirs, has nothing to do with these actions. The company pointed out that, according to the court's decision, the will does not prevent the allocation of Elena Kokeladze's marital share, and the testator could dispose of only that part of the property that belonged to him by right of personal ownership. That is, in fact, we are talking about the fact that in his will Merab Kokeladze could dispose of only a part of the company's shares and his last wife could not receive a controlling stake.
—Diana Kokeladze's position, as we believe, is not aimed at providing objective information, but at discrediting Kanonfarma and its employees, as well as causing damage to other heirs," the company said. — A significant part of her actions are aimed at destabilizing the working atmosphere and undermining the business reputation of Kanonfarma.
The company also denied claims that Kokeladze Jr. had "blocked" access to Kanonfarma for other heirs. Its representatives noted that Vyacheslav Kokeladze is not listed as an employee of Kanonfarma and does not have access to the company's internal documents.
In 2023, the entrepreneur's son registered a separate business, Kronopharm Industries, a pharmaceutical manufacturing company. The editors contacted the representatives of the organization. They replied that the information provided by Diana Kokeladze was unreliable and aimed at misleading the media.
Since the company belongs to Kokeladze Jr., Izvestia regards this response as a statement of his position.
Kronopharm Industries explained that Merab Kokeladze's share in Kanonfarma CJSC was 70% at the time of his death in 2021. In addition, the company's charter prohibits the transfer of the share of a deceased member of the company to a spouse or other heirs without the consent of other participants.
"All the participants denied Diana Kokeladze and other heirs such a transfer, so Merab Kokeladze's share passed to the company itself, after which it was redistributed among the remaining participants," the organization told Izvestia.
Representatives of the company added that the Basmanny Court of Moscow denied the widow of the businessman and the ownership of a share in the company "Kronopharm".
The mysterious font
Diana Kokeladze believes that violations were committed during the consideration of the inheritance dispute, and is preparing a statement to the UK.
—Elena divorced Merab a long time ago, and suddenly she says, 'Give me my shares,'" the woman says indignantly. — The statute of limitations has expired, but Elena says that she and Merab allegedly ran the company together. Allegedly, she was physically present at meetings where important decisions were discussed. We have requested the data from the border services. She was not in Moscow on those dates. Now they say that Elena participated in online meetings, but there is no evidence of this.
In addition, Diana Kokeladze submitted for examination the documents submitted by the businessman's ex-wife in court.
— It turned out that the font used to print the documents dated 2015 was invented only in 2018, — says the interlocutor.
A notable player
Kanonfarma Production is one of the largest Russian second—tier manufacturers, Nikolai Bespalov, Director of Development at RNC Pharma, told Izvestia. The company ranks 18th in Russia in terms of in-kind sales in the first two quarters of 2026.
"The company specializes in the production of unbranded generics, which is a very significant player in its market segment," the expert noted.
As of the second quarter of 2026, the company's portfolio included 130 international nonproprietary names (INN), the bulk of which are Moxonidine, Losartan, Metformin and Bisoprolol (they are prescribed to patients with diabetes, hypertension and chronic kidney disease. — Ed.). However, each of these innes in Russia, in addition to Kanonfarma, has from 11 to 18 manufacturers.
"It would be better for the participants in the inheritance dispute, and for the industry as a whole, if everything were resolved in the format of an agreement," Nikolai Bespalov believes. — Hypothetically, the most critical scenario is the suspension of the company's work. Heirs should understand that this can lead to serious consequences for the company. After all, we are talking about a large enterprise, it will be difficult to replace the lost volumes at once, and there are risks of drug shortages. However, other manufacturers will cover the deficit relatively easily. But for the company itself, such interruptions can have very unpleasant consequences, since it will be very problematic to re-occupy competitive niches.
How will the quarrel of the heirs turn out for the company
The likelihood of a criminal case being initiated against Diana Kokeladze is extremely low, says Albert Khaleyan, a criminal lawyer and partner at the Vector Prime Moscow Bar Association.
"If one side of the conflict claims that the documents provided by the opponents are fake, the court may order handwriting and technical expertise," he said. — The outcome of a case often depends on their results.
The conflict in the Kokeladze family and the protracted lawsuits are caused by the inaccuracy of the businessman's will, says Veronika Polyakova, managing partner of the Business Legal Group Bar Association. According to her, Merab Kokeladze assumed that he owned 100% of the company's shares.
"Such an approach is unacceptable, since securities acquired in marriage are recognized as joint property unless it is proven that they were purchased with the personal funds of one of the spouses," the expert explained. — Therefore, if we believe that Elena Kokeladze really did not conclude an agreement with her ex-husband on the division of property and a prenuptial agreement regarding shares in the company's shares, then allocating half of the company's shares in her favor is justified.
The legal dispute between Merab Kokeladze's heirs is already negatively affecting the company, Nikos Paraskevov, managing partner of the Business Legal Group Bar Association, believes. He noted that before the decision was made, the court forbade the heirs to dispose of their shares in the company's shares.
— Restrictive measures have affected the company's patents for medical products: now they cannot be sold to other manufacturers, or drug formulas can be changed, — said the expert. — And these are financial losses and a decline in production expansion. Currently, only three of the company's 11 drugs are sold on the market, and revenue for them has decreased significantly.
Inheritance disputes in business often destabilize large companies. Nikos Paraskevov cited the situation with Natura Siberica as an example. The founder of the company, Andrey Trubnikov, died in 2021 without leaving a will, which turned into a fierce struggle for inheritance between his relatives — children from his first two marriages and his third wife Anastasia Trubnikova. The businessman's first wife, Irina, forbade the use of trademarks on some of the goods, unilaterally terminating the license agreement. This led to the suspension of licenses for the use of key brands Natura Siberica and "Recipes of Grandma Agafya" and the closure of some stores. The only thing that saved the company was that the parties were able to find a compromise and split the shares, and then sell them to a strategic investor.
Disputes between heirs are especially common in situations where the testator has children from several marriages, illegitimate children, and the transfer of shares or shares in companies creates risks for business, even if there is no dispute between the heirs, said Ilya Aleschev, partner at Alimirzoev and Trofimov law firm.
— With the death of the controlling owner, a single decision-making center disappears in the company, and it is impossible to determine to whom it has passed until the disputes are over. All this time, corporate decisions are made in conditions where their legality may later be challenged by the heir," said Asiyat Alibekova, lawyer, Head of Corporate Practice at Sokolov, Trusov and Partners.
According to her, the Kanonfarma case is also complicated by the fact that it is a tightly regulated field — pharmaceuticals, where we are talking about drugs from the list of VED, public procurement. For such a company, a public shareholder conflict with mutual accusations is a serious blow to its reputation, and both counterparties and the regulator take it into account, Alibekova believes.
Переведено сервисом «Яндекс Переводчик»